The European Society for Medical Oncology (ESMO) shared a post on X:
“At ESMO24, updated data of KEYNOTE-716 and CheckMate 76K studies confirm the key role of anti-programmed cell death protein 1 (PD-1)-based immunotherapy in the adjuvant setting for patients with melanoma.”
More posts featuring ESMO.